Individualized Treatment Needed for Patients With NRAS-Mutated mCRC
January 15th 2017Activating, hotspot mutations in the NRAS gene occur in a small subset of patients with metastatic colorectal cancer. These mutations are now being identified in routine clinical practice by extended RAS genotyping.
Read More
Lapatinib Plus Whole-Brain Radiotherapy May Control Brain Metastases in HER2+ Breast Cancer
January 4th 2017An investigation of the tyrosine kinase inhibitor lapatinib plus whole-brain radiotherapy has entered into a phase II trial in the treatment of patients with brain metastases from HER2-positive breast cancer.
Read More
Expert Sheds Light on Efficacy of Dual HER2-Directed Therapy
November 15th 2016Dual HER2-directed therapy has demonstrated promising efficacy as a treatment approach for patients with breast cancer. Still, there remains a need for further research pertaining to therapies for HER2-positive patients who do do not meet the current criteria for this neoadjuvant regimen.
Read More
Expert Highlights Potential of Immunotherapy in Gastric Cancer
August 29th 2016Zev Wainberg, MD, discusses a plethora of immunotherapy agents, such as pembrolizumab (Keytruda), durvalumab, avelumab, and apatinib, for the treatment of patients with gastric cancer, as well as a number of ongoing clinical trials in this space.
Read More
Expert Explains Significance of Early Tumor Shrinkage in Metastatic Colorectal Cancer
August 10th 2016Volker Heinemann, MD, PhD, discusses the connection between early tumor shrinkage and overall survival, depth of response, and what it could mean for the future of metastatic colorectal cancer treatment.
Read More
Expert Hopeful About Emerging Options in Pancreatic Cancer Care
August 8th 2016Eileen O'Reilly, MD, discusses optimal sequencing of therapies for patients with pancreatic cancer, what potential immunotherapy has in the field, and whether the microenvironments and immune privilege within the malignancy should be understood.
Read More
Expert Shares Obstacles With Neoadjuvant Chemo in GEJ and Esophageal Cancers
July 28th 2016David Ilson, MD, PhD, discusses pre-operative chemotherapy alone versus chemotherapy plus radiation therapy in patients with esophageal and gastroesophageal-junction cancers, and how data points to the latter being the better choice.
Read More
CDK4/6 Inhibitor Shows Promise as Single Agent in HR+ Breast Cancer
July 6th 2016Maura Dickler, MD, discusses findings from the recent phase II study exploring abemaciclib as a single agent in patients with HR-positive breast cancer, along with an upcoming phase III trial looking at combination strategies.
Read More
Efforts Continue to Optimize Ibrutinib in CLL
June 2nd 2016Jennifer Brown, MD, discusses the findings and impact of the RESONATE and RESONATE-2 trials, as well as the role of ibrutinib in older and younger patients with chronic lymphocytic leukemia in both the frontline and relapsed settings.
Read More
Expert Sheds Light on Role of Next-Generation Agents in CLL
June 1st 2016Susan M. O'Brien, MD, discusses upcoming novel treatments in relapsed/refractory chronic lymphocytic leukemia, such as the next generation of inhibition with BTK, SYK, and PI3K, as well as the outcomes of the recent RESONATE-2 trial.
Read More
Molecular Testing, New Biomarkers on Horizon for Immunotherapy in RCC
May 11th 2016Mark Ball, MD, discusses the clinical, pathological, and genomic profiles of exceptional responders to anti–PD-1 therapy in renal cell carcinoma, the future of immunotherapy, and what significance genomic testing may hold.
Read More